Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis – Corrected Proof

Purpose: To report outcomes of ophthalmic evaluations in clinical studies of patients receiving fingolimod (Gilenya; Novartis Pharma AG, Basel, Switzerland) for multiple sclerosis (MS). Design: Analysis done on pooled safety data (N = 2615, all studies group) from 3 double-masked, randomized, parallel-group clinical trials (phase 2 core and extension >5 years, and phase 3 FREEDOMS and TRANSFORMS core and extension studies). Participants: Patients aged 18 to 55 years (18–60 years in phase 2 study) diagnosed with relapsing-remitting MS were included. Patients with diabetes mellitus or macular edema (ME) at screening were excluded. Intervention: Participants received fingolimod (0.5/1.25 mg), placebo, or (Read more...)

Full Story →